Medical
-
Pulmatrix has initiated a Phase 1B study of its PUR0200, an inhaled LAMA for the treatment of COPD, the company says. PUR0200 is a lactose-free formulation created using the company’s iSPERSE particle engineering technology. Pulmatrix… Read more . . .
-
Activaero has announced that its FAVORITE (flow and volume regulated inhalation technology) system is being used for additional Phase 1 studies of Ablynx’s Nanobody ALX-0171 for the treatment of respiratory syncytial virus (RSV). Results from… Read more . . .
-
Acorda Therapeutics announced results from a clinical study of the pharmacokinetics, safety, and tolerability of its diazepam nasal spray for the treatment of cluster seizures in epilepsy patients at the recent International Congress of the… Read more . . .
-
According to Insmed, a Phase 3 study of more than 300 cystic fibrosis patients has demonstrated the non-inferiority of once-daily Arikace inhaled liposomal amikacin to twice-daily TOBI tobramycin inhalation solution, meeting the study’s primary endpoint.… Read more . . .
-
Israeli device company Inspiro Medical has announced that a safety and efficacy study of formoterol delivered by the Inspiromatic dry powder inhaler for the treatment of asthma in children met both its primary and secondary… Read more . . .
-
According to Genoa Pharmaceuticals, a pre-clinical study conducted at McMaster University demonstrated that the company’s GP-101 inhaled pirfenidone demonstrated statistically significant greater anti-fibrotic effect in an in vivo model of pulmonary fibrosisi than did higher… Read more . . .
-
According to reports, Johnson & Johnson described development of a ketamine nasal spray for the treatment of depression during a meeting with analysts on May 23, 2013. The product is not listed among the company’s… Read more . . .
-
A new consortium described as a “series of conceptual research projects in the area of nasal physiology, function and drug delivery” that “aims to enhance understanding in the area of upper respiratory tract disorders and… Read more . . .
-
A study presented at ATS 2013 found that over 40 percent of uninsured patients treated for COPD at a US clinic did not actually have COPD. Researchers from Northeast Ohio Medical University and Saint Elizabeth… Read more . . .
-
Prosonix has started a Phase 2 safety and dose-ranging study of PSX1002 inhaled glycopyrronium bromide, a long-acting muscarinic antagonist (LAMA), in patients with moderate-to-severe COPD, the company has announced. The suspension formulation of PSX1002 engineered… Read more . . .
Featured event:
Upcoming Events
Sponsored by Intertek,, hosts of
The Inhaled & Nasal Biologics | DNA Forum
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
No events are found.